A recent clinical trial revealed that the drug pelacarsen, designed to lower the risk of cardiovascular events, did not meet its primary endpoint. Although it reduced lipoprotein (a) levels in patients, it had no impact on mortality rates or serious cardiac events. Researchers emphasize the importance of this study, which could challenge the role of lipoprotein (a) in cardiovascular diseases.